On 27 August 2010, the European Medicines Agency announced that the agency's Committee for Medicinal Products for Human Use would be launching a review of Pandemrix in light of the "limited number of cases"[21] reported in Finland and Sweden, so as to "determine whether there is evidence for a causal association".[22]